Oxford, England, June 25, 2020
- 68 genes associated with high-risk of developing severe COVID-19 identified from AI-analysis of hospitalized patients from UK Biobank
- The damaging immune response factors identified are common across all patients with all co-morbidities, giving potential for biomarkers to stratify people at high-risk of severe COVID-19
- A new cluster of genes was identified converging on plasma membrane repair, clotting and wound healing
- Several druggable protein targets and pathways were found, creating new opportunities for drug repurposing and accelerated drug development
Oxford, England, June 25, 2020 /PRNewswire/ -- Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. See results on the pre-publication site, medRxiv.
Prior to an effective and widely available vaccine, PrecisionLife's insights may help to identify patients who are at greatest risk of developing the most severe forms of COVID-19. They can inform the development of biomarker driven tests, targeted shielding and new therapeutic strategies, with the aim of identifying high-risk people, reducing disease burden and improving survival rates.
Established Genome Wide Association Studies (GWAS) approaches have been limited by the heterogenous nature of COVID-19, making it difficult to clearly explain the wide range of symptoms and impacts of predisposing comorbidities associated with the disease. The study has overcome this barrier by evaluating combinations of genetic features, which is not possible with existing GWAS approaches.
Using a combinatorial (high-order epistasis) analysis approach, PrecisionLife identified 68 protein-coding genes that were highly associated with severe COVID-19, nine of which have been previously linked to differential response to SARS-CoV-2. These 68 genes include several druggable protein targets and pathways, nine of which are targeted by drugs that have reached at least Phase I clinical trials.
"This is our second study specifically looking at host genomics to identify those most at risk and find opportunities to treat patients with later stage severe disease where host immune processes begin to run out of control," said Dr Steve Gardner, CEO of PrecisionLife.
"We know that systemic remodelling, leaky vasculature and micro-clotting can cause severe issues in COVID-19 patients in lungs as well as other organs. We are encouraged that several of the genes identified relate to lipid programming, beta-catenin and protein kinase C signalling whose processes converge in a central pathway involved in plasma membrane repair, clotting and wound healing. This pathway is largely driven by calcium ion activation, which is a known serum biomarker associated with severe COVID-19 and ARDS. We intend to perform further analyses to investigate this hypothesis. We are also seeking to further validate 12 genes associated with dysfunctional immune response that are the first hint at a potential genetic signature for enhanced risk of flipping into a severe disease state."
Full release can be accessed HERE.
PrecisionLife Ltd was founded in 2015, built on a shared vision to bring a new level of analytical capability to computational biology, genomic medicine and healthcare. Its powerful data analytics platform is built on a unique mathematical framework and over 30 years' experience in delivering new technologies and products to enable the discovery of richer and more useful links between patients, disease, targets and drugs.
Headquartered in the UK, PrecisionLife also has operations in the US, Denmark and Poland.
Dr Steve Gardner